Morepen Laboratories gets certification from UK for its medical devices manufacturing facility at Baddi

Morepen Laboratories Ltd. has received the ISO-13485 certification from BSI (British Standards Institution, U.K.) for its State of-the-art medical devices manufacturing facility at Baddi (Himachal Pradesh). The certification has been awarded for the manufacturing, distribution and after sales service of all point-of-care diagnostic medical devices and their accessories manufactured at the company’s facility in Baddi.

This certification is recognized by most regulators across the globe including those in the United Kingdom and the European Union. Compliance with this standard ensures the consistent production, delivery and after sales service of medical devices that are safe for their intended purpose.

Sushil Suri, Chairman and Managing Director,Morepen Laboratories Ltd., said, “This ISO-13485 certification opens new vistas for Morepen to export its diagnostic devices to various countries across the globe and also to seek CE (Conformité Européene) Certification for the European Union. Having complied with all the important technical and regulatory guidelines for the Quality Management Systems as per ISO-13485, the company is confident of securing CE certification for its products as a next step.”

With the grant of ISO-13485 Certification, Morepen Labs’ diagnostic devices are expected to become the preferred choice for customers seeking high quality products manufactured as per best industry practices, Suri claimed.

The company has recently launched a wide range of essential products being required to combat the growing menace of Coronavirus disease and to prevent further spread of this disease in the country. These include non-contact Infrared Thermometers, alcohol-based Hand Sanitizers, Hand Wash, Hand Rubs and 2-Ply/ 3-Ply Face Masks, all under its umbrella brand — Dr. Morepen.

The Company has also recently received license to manufacture Hydroxychloroquine (HCQ) from State Drug Controller (HP) for its Baddi plant in Himachal Pradesh and is working towards commercializing the production of HCQ in both API as well as tablets form. HCQ is a prescription based drug commonly being recommended to Corona patients under treatment for the disease. India is taking a lead in supplying HCQ to the rest of the world including the USA. India is the largest producer of HCQ and will continue to retain its leadership position in this time of crisis. 

Website | + posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: